Background
The failure of a recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 in a phase 2b efficacy study in humans calls for efforts to develop novel vaccination strategies.
Methods
In this study, we developed a recombinant replicationcompetent modified vaccinia Tiantan (MVTT), namely rMVTT SIVgpe , as a mucosal vaccine expressing SIVmac Gag, Pol and Env. The immunogenicity and efficacy of rMVTT SIVgpe was studied in combination with an rAd5based vaccine rAd5 SIVgpe in Chinese macaques (Macaca mulatta) without the protective MHC class I allele Mamu-A*01. rMVTT SIVgpe was given through intranasal and oral inoculations whereas rAd5 SIVgpe was given through intramuscular injection. Four macaques in each of the four study groups received the following prime and boost vaccinations: rMVTT SIVgpe /rAd5 SIVgpe ; rMVTT SIVgpe /rAd5 SIVgpe , twice; rAd5 SIVgpe /rAd5 SIVgpe ; and placebo controls, respectively.
Results
We found that the heterologous rMVTT SIVgpe /rAd5 SIVgpe regimen elicited cellular immune responses with enhanced magnitude, breadth, sustainability, and polyfunctionality when compared with the homologous rAd5 SIVgpe regimen. Higher levels of neutralizing antibody (Nab) responses were also induced by the rMVTT SIVgpe / rAd5 SIVgpe regimen. These Nab responses, however, neutralized SIVmac1A11 but not SIVmac239. The additional round of rMVTT SIVgpe /rAd5 SIVgpe vaccinations did not enhance the immune responses further. After intrarectal challenge with a pathogenic and Chinese macaqueadapted SIVmac239 (5 × 10 5 TCID 50 per animal), one of four monkeys vaccinated with the rMVTT SIVgpe /rAd5 SIVgpe regimen was fully protected whereas the rest showed an average of 1.96 log and 2.22 log reduction of peak and setpoint (6 weeks post challenge) viral loads as compared with control animals.
Conclusion
These data demonstrate that the rMVTT SIVgpe /rAd5 SIVgpe regimen induced durable partial immune control of a pathogenic, neutralization-resistant SIVmac239 challenge. Our findings have critical implications for further optimization of vaccination strategies against HIV-1 by engaging the mucosal immune system. 
